Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for MRD in High-risk DLBCL Post-aHSCT
NCT03298412Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL), sponsored by Amgen. Primary endpoint: MRD-Negative Rate at the End of Cycle 1 at 12 weeks. Started May 2018; status: terminated.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03298412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298412.